PALVELLA THERAPEUTICS
Palvella Therapeutics is a start-up life sciences company that focuses on relentlessly and selflessly serving abandoned patient populations with therapies. The company specializes in developing therapies that specifically target the root cause of the disease. Palvella Therapeutics was founded in 2015 and headquartered in Wayne, Pennsylvania.
PALVELLA THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Life Science Therapeutics
Founded:
2015-01-01
Address:
Wayne, Pennsylvania, United States
Country:
United States
Website Url:
http://www.palvellatx.com
Total Employee:
1+
Status:
Active
Contact:
(484) 253-1460
Email Addresses:
[email protected]
Total Funding:
59.44 M USD
Technology used in webpage:
Amazon Route 53 Squarespace Hosted Mimecast
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Autobahn Therapeutics
Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Advisors List
Current Employees Featured
Founder
Investors List
Opaleye Management
Opaleye Management investment in Series C - Palvella Therapeutics
BioAdvance
BioAdvance investment in Series C - Palvella Therapeutics
Samsara BioCapital
Samsara BioCapital investment in Series C - Palvella Therapeutics
CAM Capital
CAM Capital investment in Series C - Palvella Therapeutics
BVF Partners
BVF Partners investment in Series C - Palvella Therapeutics
Adams Street Partners
Adams Street Partners investment in Series C - Palvella Therapeutics
Agent Capital
Agent Capital investment in Series C - Palvella Therapeutics
Ligand Pharmaceuticals
Ligand Pharmaceuticals investment in Series C - Palvella Therapeutics
Nolan Capital
Nolan Capital investment in Series C - Palvella Therapeutics
Ligand Pharmaceuticals
Ligand Pharmaceuticals investment in Corporate Round - Palvella Therapeutics
Official Site Inspections
http://www.palvellatx.com Semrush global rank: 4.83 M Semrush visits lastest month: 1.87 K
- Host name: 23.185.0.3
- IP address: 23.185.0.3
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Palvella Therapeutics"
Palvella Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Phone Number (484) 253-1460 Palvella Therapeutics is a start-up life sciences company that focuses on relentlessly …See details»
Investor Relations - Palvella Therapeutics
Apr 2, 2025 Corporate Profile. Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients …See details»
Committee Composition - Palvella Therapeutics
Overview of Committee Composition and Member Roles; Director Name Audit Committee Compensation Committee Nominating and Corporate Governance CommitteeSee details»
Advocacy / Partnerships - Palvella Therapeutics
National Organization for Rare Disorders NORD is a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them. NORD, along with its …See details»
Palvella Therapeutics - LinkedIn
Palvella Therapeutics (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic ...See details»
Palvella Therapeutics - Leadership Team - The Org
The Leadership Team at Palvella Therapeutics is responsible for strategic decision-making and guidance across the organization, ensuring alignment with the company’s mission to develop …See details»
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief …
Oct 17, 2024 Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, …See details»
Palvella Therapeutics, Inc. - Drug pipelines, Patents
Www.palvellatx.com. Last update 06 Mar 2025. Overview. Pipeline. Deal. Translational Medicine. Profit. Grant & Funding(NIH) Investment. Financing. ... The statistics for drugs in the Pipeline is the current organization and its …See details»
Palvella Therapeutics Overview | SignalHire Company Profile
By Q2 2020, Palvella Therapeutics has participated in at least 4 funding rounds and has raised a minimum of 64.2M. Funding increased noticeable in Q2 2020 — by 40.2M compared to the …See details»
Palvella Therapeutics, Inc. Company Information - Funding, …
Get information on funding, investors, industries, and more for Palvella Therapeutics, Inc.. See Palvella Therapeutics, Inc. company profile and funding data.See details»
Palvella Therapeutics Announces Closing of Merger with Pieris ...
Dec 13, 2024 For more information, please visit www.palvellatx.com or follow the Company on LinkedIn. QTORINâ„¢ rapamycin is for investigational use only and has not been approved or …See details»
Palvella Therapeutics Inc. | Life Sciences PA
Palvella is a biopharmaceutical company committed to serving patients with debilitating rare, genetic diseases through the development and commercialization of life-changing, …See details»
Palvella Therapeutics - Overview, News & Similar companies
Mar 9, 2023 View Palvella Therapeutics (www.palvellatx.com) location in Pennsylvania, United States , revenue, industry and description. Find related and similar companies as well as …See details»
Investors - Palvella Therapeutics
Oct 15, 2024 November 7, 2024 in Uncategorized Palvella Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of QTORINâ„¢ 3.9% Rapamycin Anhydrous Gel (QTORINâ„¢ …See details»
Palvella Therapeutics to Host Full Year 2024 Financial
WAYNE, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and …See details»
Palvella Therapeutics Announces Abstract Highlighting the …
2 days ago For more information, please visit www.palvellatx.com or follow Palvella on LinkedIn or X (formerly known as Twitter). QTORINâ„¢ rapamycin is for investigational use only and has …See details»
Palvella Therapeutics Granted Additional U.S. Patent for QTORIN ...
3 days ago Palvella Therapeutics Inc. Fifth issued patent in the U.S. for QTORINâ„¢ rapamycin with anticipated patent life extending into 2038. QTORINâ„¢ rapamycin has the potential to be …See details»
Release Details - ir.palvellatx.com
Feb 10, 2025 Expansion reflects Palvella's commitment to serving all patients affected by microcystic lymphatic malformations (microcystic LMs) Company remains on track to report …See details»
Our Programs - Palvella Therapeutics
Microcystic Lymphatic Malformations (Micro LM) is a rare genetic disease of the lymphatic system that presents on the skin, characterized by abnormal vessels or cysts that lead to chronic …See details»
Release Details - ir.palvellatx.com
3 days ago Fifth issued patent in the U.S. for QTORINâ„¢ rapamycin with anticipated patent life extending into 2038 QTORINâ„¢ rapamycin has the potential to be the first approved therapy …See details»